224 related articles for article (PubMed ID: 12194808)
1. Hormone-refractory Prostate Cancer.
Rini BI; Small EJ
Curr Treat Options Oncol; 2002 Oct; 3(5):437-46. PubMed ID: 12194808
[TBL] [Abstract][Full Text] [Related]
2. Secondary hormonal manipulation of prostate cancer.
Harris KA; Small EJ
Curr Urol Rep; 2001 Jun; 2(3):224-30. PubMed ID: 12084269
[TBL] [Abstract][Full Text] [Related]
3. Treatment options in hormone-refractory prostate cancer: current and future approaches.
Harris KA; Reese DM
Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
[TBL] [Abstract][Full Text] [Related]
4. Secondary hormonal manipulation of prostate cancer.
Small EJ; Harris KA
Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):24-30. PubMed ID: 12198635
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
Rehman Y; Rosenberg JE
Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
[TBL] [Abstract][Full Text] [Related]
6. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for hormone-refractory prostate cancer.
Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
[TBL] [Abstract][Full Text] [Related]
8. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
11. Role of estrogens in the secondary hormonal manipulation of hormone refractory prostate cancer.
Siddiqui K; Abbas F; Biyabani SR; Ather MH; Talati J
J Pak Med Assoc; 2004 Sep; 54(9):445-7. PubMed ID: 15518364
[TBL] [Abstract][Full Text] [Related]
12. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
13. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
Di Lorenzo G; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
[TBL] [Abstract][Full Text] [Related]
14. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
15. Endocrine therapy: where do we stand and where are we going?
Schröder FH
Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
17. Anti-androgens and other hormonal therapies for prostate cancer.
Richie JP
Urology; 1999 Dec; 54(6A Suppl):15-8. PubMed ID: 10606279
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore.
Ngo LS; Yeo A; Wong AS; Tay MH
Ann Acad Med Singap; 2007 Oct; 36(10):811-4. PubMed ID: 17987231
[TBL] [Abstract][Full Text] [Related]
19. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients.
Miyoshi Y; Uemura H; Nakamura M; Hasumi H; Sugiura S; Makiyama K; Nakaigawa N; Kishida T; Ogawa T; Yao M; Kubota Y
Int J Clin Oncol; 2005 Jun; 10(3):182-6. PubMed ID: 15990966
[TBL] [Abstract][Full Text] [Related]
20. Medical therapy of prostate cancer. A review.
Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P
Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]